News&Resources

Partner Alyson DiLena will be a speaker on the Biotech and Pharma Panel at this year’s Joint Patent Practice Seminar held on June 15, 2022 at the APA Hotel Woodbridge in Iselin, NY.  She will be presenting on Novartis Pharmaceutical Corporation v. Accord Healthcare, Inc.’s analysis of written description for […]

In early 2009, AstraZeneca filed for a preliminary injunction in New Jersey District Court to prevent SSJR client Apotex from launching its generic version of AstraZeneca’s Pulmicort Respules® product. During the hearing, an Apotex witness identified certain attorney communications as a reason for certain actions taken. AstraZeneca asserted this amounted to a […]

In early 2009, Astra Zeneca filed litigation in New Jersey District Court to prevent SSJR client Apotex from launching its generic version of AstraZeneca’s Pulmicort Respules® product. During discovery, AstraZeneca, a Swedish company, withheld numerous communications with in-house counsel on the grounds of attorney-client privilege. Recognizing that these communications should not have […]

In early 2009, Astra Zeneca filed for a preliminary injunction in New Jersey District Court to prevent SSJR client Apotex from launching its generic version of AZ’s Pulmicort Respules (budesonide). AZ asserted among other things that Apotex’s launch would infringe the kit claims in U.S. Patent No. 6,598,603 and No. 6,899,099. The […]

The District Court for the District of New Jersey has ruled in favor of Sandoz, Inc., denying Otsuka Pharmaceutical’s attempt to amend an ANDA Complaint to add new claims for commercial and willful infringement. After subsequent briefing and oral argument, the District Court affirmed a magistrate judge’s ruling that the additional claims […]